scispace - formally typeset
H

Hui Quan

Researcher at Merck & Co.

Publications -  75
Citations -  11543

Hui Quan is an academic researcher from Merck & Co.. The author has contributed to research in topics: Rofecoxib & Placebo. The author has an hindex of 33, co-authored 69 publications receiving 11295 citations. Previous affiliations of Hui Quan include United States Military Academy.

Papers
More filters
Journal ArticleDOI

Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

TL;DR: Daily treatment with alendronate progressively increases the bone mass in the spine, hip, and total body and reduces the incidence of vertebral fractures, the progression of vertebra deformities, and height loss in postmenopausal women with osteoporosis.
Journal ArticleDOI

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

TL;DR: Treatment with rofecoxib was associated with a significantly lower incidence of PUBs than treatment with NSAIDs, based on survival analysis of time to first PUB diagnosis, using Pubs that met pre-specified criteria judged by a blinded, external adjudication committee.
Journal Article

Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.

TL;DR: The data suggest that acute sodium retention by nonsteroidal anti-inflammatory drugs in healthy elderly subjects is mediated by the inhibition of Cox-2, whereas depression of GFR is due to inhibition ofcox-1.